Pfizer shares, which had risen Tuesday morning after improved demand for the Covid vaccine, dropped 2.3% after Kennedy's ...

Pfizer's Super Bowl ad received mixed reactions on social media, but many criticized the pharma giant for saying it will ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.DozQrLpG.js ...

Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

Pfizer’s contributions to animal health date back several decades, during which the company played a significant role in ...

Eliquis, a blood thinner marketed in partnership with Bristol Myers Squibb, is Pfizer's largest revenue stream at the moment.

Other fact-checking organizations have debunked the claim; Reuters and AFP have also fact-checked similar claims that circulated in 2022 and 2023 ...

On an adjusted basis, the company earned 63 cents per share for the three months ended Dec. 31, compared with the average ...

Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...

Pfizer PFE reported fourth-quarter 2024 adjusted earnings per share of 63 cents, which beat the Zacks Consensus Estimate of ...

Pfizer reported strong 2024 profits Wednesday on the same day the Connecticut Attorney General’s office released a statement ...

Jefferies analyst Akash Tewari increased the price target for Pfizer (NYSE:PFE) shares from $33.00 to $34.00, while reiterating a Buy rating on the stock. Currently trading at $25.72, near its 52-week ...